Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Sex-specific thresholds of high-sensitivity troponin identify more women with myocardial injury

23 Oct 2019

Implementing a high-sensitivity cardiac troponin I assay with sex-specific diagnostic thresholds results in identifying five times more women than men with myocardial injury, reports a study.

“Despite this increase, women received approximately one-half the number of treatments for coronary artery disease as men, and outcomes were not improved,” the investigators said.

To evaluate the impact of using a high-sensitivity cardiac troponin I assay with sex-specific thresholds for myocardial infarction (MI), the investigators enrolled consecutive patients with suspected acute coronary syndrome in a stepped-wedge, cluster-randomized controlled trial across 10 hospitals.

Myocardial injury was defined as high-sensitivity cardiac troponin I concentration >99th centile of 16 ng/l in women and 34 ng/l in men. Recurrent MI or cardiovascular (CV) death at 1 year was the primary outcome.

Overall, 48,282 patients (47 percent women) were eligible for the study. Use of the high-sensitivity cardiac troponin I assay with sex-specific thresholds led to a 42-percent increase in myocardial injury in women and a 6-percent risk in men.

Following this implementation, women with myocardial injury were still less likely than men to undergo coronary revascularization (15 percent vs 34 percent) and to receive treatment such as dual antiplatelet (26 percent vs 43 percent), statin (16 percent vs 26 percent) or other preventive therapies (p-all<0.001).

Eighteen percent and 17 percent of women with myocardial injury experienced recurrent MI or CV death 1 year before and after implementation, respectively (adjusted hazard ratio [aHR], 1.11, 95 percent CI, 0.92–1.33), as compared with 18 percent and 15 percent of men (aHR, 0.85, 0.71–1.01).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.